Literature DB >> 10347760

Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection.

F Costa1, V L Pereira-Chioccola, M Ribeirão, S Schenkman, M M Rodrigues.   

Abstract

Trypanosoma cruzi. the protozoan parasite that causes Chagas' disease, does not synthesize sialic acid, but expresses a trans-sialidase (TS) that catalyzes the transfer of sialic acid from host glycoconjugates to the parasite surface. Here, we review studies that characterize the immune response to the catalytic domain of the enzyme in humans during Chagas' disease or in mice following immunization with the TS gene. In both cases, there are antibodies that strongly inhibit the enzymatic activity and generation of interferon-gamma-producing T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347760     DOI: 10.1590/s0100-879x1999000200013

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  6 in total

1.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis.

Authors:  Marcelo Sousa Silva; Duarte Miguel F Prazeres; Andreia Lança; Jorge Atouguia; Gabriel Amaro Monteiro
Journal:  Parasitol Res       Date:  2009-07-07       Impact factor: 2.289

3.  Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.

Authors:  O K Giddings; C S Eickhoff; N L Sullivan; D F Hoft
Journal:  Infect Immun       Date:  2010-01-04       Impact factor: 3.441

4.  Trans-sialidase-based vaccine candidate protects against Trypanosoma cruzi infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype.

Authors:  Estefanía Prochetto; Carolina Roldán; Iván A Bontempi; Daiana Bertona; Luz Peverengo; Miguel H Vicco; Luz M Rodeles; Ana R Pérez; Iván S Marcipar; Gabriel Cabrera
Journal:  Oncotarget       Date:  2017-05-25

Review 5.  Theft and Reception of Host Cell's Sialic Acid: Dynamics of Trypanosoma Cruzi Trans-sialidases and Mucin-Like Molecules on Chagas' Disease Immunomodulation.

Authors:  Leonardo Marques da Fonseca; Kelli Monteiro da Costa; Victoria de Sousa Chaves; Célio Geraldo Freire-de-Lima; Alexandre Morrot; Lucia Mendonça-Previato; Jose Osvaldo Previato; Leonardo Freire-de-Lima
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

6.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.